Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis

Attia‐Sobol, Jocelyne; Ferriere, J. P.; Curé, Hervé; Kwiatkowski, Fabrice; Jl, Achard; Verrelle, Pierre; Feillel, V.; Latour, M. De; Lafaye, C.; Deloche, Claire; Dauplat, J.; Doly, Anne; Rozan, R; Chollet, P.

doi:10.1016/s0959-8049(05)80292-8

Cited by 50 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The locoregional outcomes we demonstrated were excellent and corroborated the results reported in the recent MDACC study, as well as other published studies that used a median dose of 50 to 60 Gy with daily fractionation for IBC and demonstrated 5-year LRC rates ranging from 78% to 92% (20,21,24,29,30). Our radiation technique differed from those described in previous studies in several important ways: (1) mastectomy scar boost was not routinely advocated, and performed in only a small fraction (11%) of patients (2) skin bolus was used daily to ensure that the entire surface of the skin was included within the prescription isodose line; and (3) the CW was most often treated with electron therapy to minimize the radiation dose to critical normal structures such as heart and lung.…”

Section: Discussionsupporting

confidence: 90%

Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era

Damast

Montgomery

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era

Damast

Montgomery

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…49 Two clinical forms of IMC have been described in dogs 49 and women. 1,52,71 Primary IMC refers to IMC occurrence in a dog without previous history of mammary nodules, whereas secondary IMC includes IMC occurrence in a dog with previous mammary tumors. Secondary IMC is further classified into two types: postsurgical secondary (IMC after surgical excision of a previous mammary tumor) and non-postsurgical secondary (a previous mammary tumor not surgically treated that leads to IMC).…”

mentioning

confidence: 99%

Histological, Immunohistological, and Ultrastructural Description of Vasculogenic Mimicry in Canine Mammary Cancer

et al. 2009

View full text Add to dashboard Cite

Canine inflammatory mammary cancer (IMC) and human inflammatory breast cancer (IBC) are the most aggressive and lethal type of mammary cancer in female dogs and in women. The generation of microvascular channels by malignant tumor cells (endothelial-like cells [ELCs]) without endothelial cell participation (vasculogenic mimicry) has been reported in human breast cancer, including IBC, and is considered a new type of tumor angiogenesis. The aim of this study was to investigate the presence of ELCs in highly malignant canine mammary tumors (IMC and non-IMC) by histology, inmunohistochemistry (pancytokeratin, cytokeratin 14, vimentin, actin, desmin, vWF, CD31, and CD34), and electron microscopy. This retrospective study included 21 female dogs with diagnoses of IMC and 20 animals with metastatic grade III noninflammatory malignant mammary tumors (MMT). IMC tumors (33.33%) and MMT (5%) showed ELCs forming structures similar to small capillaries. The histological, immunohistochemical (positive to AE1/AE3 and cytokeratin 14, mostly negative to endothelial markers), and ultrastructural characteristics of these cells indicated vasculogenic mimicry. The higher frequency of this phenomenon in inflammatory versus noninflammatory canine mammary cancer is in agreement with previous studies in experimental and spontaneous human IBC, and it could be in relation with the extremely high lymphangiogenic capacity and metastatic lymphangiotropism characteristics of inflammatory breast cancer.

show abstract

“…PEV2 describes a breast tumor causing edema and inflammatory signs that involve less than half the breast while changes associated with PEV3 involve more than half the breast surface. The criteria for PEV2 and PEV3 have been modified further to include a time interval of a less than or equal to 4 months to allow for distinction between IBC and a neglected LABC [19]. However, the PEV classification system is not widely used outside certain institutions.…”

Section: Reviewmentioning

confidence: 99%

Biology and management of inflammatory breast cancer

Dawood¹

2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Inflammatory breast cancer is an aggressive subtype of a locally advanced breast cancer that is thought to account for approximately 1-5% of all newly diagnosed breast cancers diagnosed in the USA. Historically, IBC was considered to be a uniformly fatal disease with less than 5% of patients surviving past 5 years. With the advent of a multidisciplinary approach to management, survival outcomes have improved with 5-year survival rates of over 40% being reported. Research efforts are now focused on trying to better understand the epidemiological and molecular characteristics of this disease to further improve survival. Two genes, Rhoc GTPase and WISP3, have been identified that have been found to be concordantly altered in the majority of inflammatory breast cancer tumors and may serve as potential targets for future therapeutic agents. The purpose of this review is to summarize the latest epidemiological and molecular characteristics of IBC, describe the difficulties encountered in trying to clinically diagnose this entity, highlight the importance of a multidisciplinary approach and present some of the latest data on the management of this disease.

show abstract

Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis

Cited by 50 publications

References 18 publications

Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era

Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era

Histological, Immunohistological, and Ultrastructural Description of Vasculogenic Mimicry in Canine Mammary Cancer

Biology and management of inflammatory breast cancer

Contact Info

Product

Resources

About